Center-based Care for Pulmonary Hypertension: A European Perspective, Advances in Pulmonary Hypertension, J. Simon R. Gibbs, MD, FRCP, Olivier Sitbon, MD, PhD

While this article may not be the most recent, it continues to hold value as a point of reference for those seeking insights into the organization of pulmonary hypertension care in France and UK. Although some information might require updating, its core principles remain relevant. Both France and the UK have aimed to concentrate pulmonary […]

Center-based Care for Pulmonary Hypertension: A European Perspective, Advances in Pulmonary Hypertension, J. Simon R. Gibbs, MD, FRCP, Olivier Sitbon, MD, PhD Read Post »

“Artificial intelligence in healthcare and education”, BDJ, May 26, 2023

“AI has the potential to bring about positive changes in healthcare and to empower patients by providing them with more control over their health”, reads an article in the BDJ published on May 26, 2023, which, interestingly, was entirely written by Chat GPT, an AI conversation tool developed by Open AI! Manas Dave and Neil Patel,

“Artificial intelligence in healthcare and education”, BDJ, May 26, 2023 Read Post »

Study on Patient-Reported Outcome Measures for Assessment of Health-Related Quality of Life in Patients With Pulmonary Hypertension, CHEST, November 2022

Pulmonary hypertension significantly affects patients’ quality of life. A review of published literature and clinical trials in pulmonary hypertension was conducted by the authors of this study to identify and evaluate patient-reported outcome measures (PROMs) that assess pulmonary hypertension-specific HRQoL for use in clinical studies. To assess treatment benefits and patient experiences, various PROMs were

Study on Patient-Reported Outcome Measures for Assessment of Health-Related Quality of Life in Patients With Pulmonary Hypertension, CHEST, November 2022 Read Post »

Exploring Geographic Barriers to Care Access for Patients With Pulmonary Arterial Hypertension in the US, a study presented at the American Thoracic Society (ATS) Annual Congress, May 19-24, 2023

A recent article in Drug Topics, reports on the findings of a study presented at the 2023 American Thoracic Society International Conference, held from May 19 to 24 in Washington, DC, which reveals that the majority of patients with pulmonary arterial hypertension (PAH) live in an area that has a shortage of health care professionals,

Exploring Geographic Barriers to Care Access for Patients With Pulmonary Arterial Hypertension in the US, a study presented at the American Thoracic Society (ATS) Annual Congress, May 19-24, 2023 Read Post »

Currently enrolling: HYPERION Phase 3 clinical trial to evaluate Sotatercept on top of background pulmonary arterial hypertension therapy in newly diagnosed intermediate-and high-risk patients

This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate sotatercept when added to background pulmonary arterial hypertension therapy in newly diagnosed intermediate- or high risk pulmonary arterial hypertension participants. The estimated enrolment is participants is 662 and the estimated completion date is August 31, 2028. The sponsor is Acceleron Pharma, Inc., a wholly-owned

Currently enrolling: HYPERION Phase 3 clinical trial to evaluate Sotatercept on top of background pulmonary arterial hypertension therapy in newly diagnosed intermediate-and high-risk patients Read Post »

May 20 is “International Clinical Trials Day”, a day to raise awareness about clinical trials and their contribution to public health

The International Clinical Trials Day is organised yearly on May 20, since 2014, by the Association of Clinical Research Professionals (ACRP), as an opportunity for the clinical research community to to celebrate what has been accomplished in this field and recommit to push even further. Learn more about International Clinical Trials Day at this link

May 20 is “International Clinical Trials Day”, a day to raise awareness about clinical trials and their contribution to public health Read Post »

Pulmonary endarterectomy (PEA) Leads to Long-term QOL Improvement in People With CTEPH, study suggests, American Journal of Managed Care

Pulmonary endarterectomy (PEA) is the recommended first-line treatment for patients with chronic thromboembolic pulmonary hypertension (CTEPH), if they qualify for the procedure. Alternative therapies include balloon pulmonary angioplasty (BPA) or medical therapy. An article by Jared Kaltwasser for the American Journal of Managed Care, dated April 17, 2023, presents the results of a Swedish single

Pulmonary endarterectomy (PEA) Leads to Long-term QOL Improvement in People With CTEPH, study suggests, American Journal of Managed Care Read Post »

Findings of a study published in Thorax (BMJ Journals) highlights the importance of integrating pulmonary arterial hypertension patients’ perceptions in the elaboration of clinical trials – May 4, 2023

The aim of this study was to investigate the value given by patients’ and caregivers’ to components of composite outcomes in pulmonary arterial hypertension (PAH) clinical trials. There were 335 participants, of which 257 were patients with pulmonary arterial hypertension. The study findings revealed that most outcomes were considered of major or mild-to-moderate importance to

Findings of a study published in Thorax (BMJ Journals) highlights the importance of integrating pulmonary arterial hypertension patients’ perceptions in the elaboration of clinical trials – May 4, 2023 Read Post »

“Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension”, New England Journal of Medicine, April 20, 2023

A recent article titled “Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension”, published in the New England Journal of Medicine, reports on the results of a multicenter, double-blind, phase 3 trial in which adults with pulmonary arterial hypertension (functional class II or III) who were receiving stable background therapy were randomly assigned

“Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension”, New England Journal of Medicine, April 20, 2023 Read Post »

A study investigating how intimacy is affected by pulmonary hypertension, initiated by the Board of the Dutch Pulmonary Hypertension Association, was published in “Clinical Research in Cardiology” on April 30, 2023

The aim of this study was to investigate sexual functioning in men and women with pulmonary hypertension. The initiative to undertake this study was taken some years ago by members of the Board of Stichting Pulmonale Hypertensie, the Dutch Pulmonary Hypertension Association, who asked healthcare professionals to address the issue of sexuality in relation to

A study investigating how intimacy is affected by pulmonary hypertension, initiated by the Board of the Dutch Pulmonary Hypertension Association, was published in “Clinical Research in Cardiology” on April 30, 2023 Read Post »

On April 20, 2023, the Pulmonary Vascular Research Institute (PVRI) launched a survey about access to pulmonary hypertension education, diagnosis and care.

The PVRI survey is addressed at health care professionals to identify gaps and challenges that limit access to quality professional clinical care for patients with pulmonary hypertension. The results will be used to develop action plans to help address local needs, mainly in the education, diagnosis, and treatment of pulmonary vascular diseases. The survey results

On April 20, 2023, the Pulmonary Vascular Research Institute (PVRI) launched a survey about access to pulmonary hypertension education, diagnosis and care. Read Post »

Minimally invasive robot-assisted lung transplant surgery (without opening the chest) carried out in Spain at the Val d’Hebron hospital, April 17, 2023

Commentary by Prof. Olaf Mercier, M.D., Ph.D., Thoracic Surgeon, Marie Lannelongue Hospital, France Minimally invasive surgery has shown its value in lung resection surgery by reducing the impact of the surgical procedure and accelerating recovery after the operation. These techniques did not allow for lung transplantation, which is a more risky procedure because the connections

Minimally invasive robot-assisted lung transplant surgery (without opening the chest) carried out in Spain at the Val d’Hebron hospital, April 17, 2023 Read Post »

“PH Roundtable: Pros and Cons of the 2022 ERS/ESC Guidelines: Practicality vs Real World View”, Advances in Pulmonary Hypertension, April 13, 2023

This article, published in Advances in Pulmonary Hypertension, refers to a round table covened to discuss the 2022 joint ERS/ESC guidelines on pulmonary hypertension. The round table was attended by Dr Thenappan Thenappan, University of Minnesota, Minneapolis; Dr Marc Humbert, Université Paris-Saclay, Paris; Dr Vallerie McLaughlin, University of Michigan, Ann Arbor; Dr Hilary DuBrock, Mayo

“PH Roundtable: Pros and Cons of the 2022 ERS/ESC Guidelines: Practicality vs Real World View”, Advances in Pulmonary Hypertension, April 13, 2023 Read Post »

“European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension”, European Journal of Heart failure, March 16, 2023

The “European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension” were published on the European Journal of Heart Failure on March16, 2023. The indicators may be used to quantify and improve adherence to guideline-recommended clinical practice and improve patient outcomes. Quoting Gergely Meszaros, pulmonary hypertension patient advocate

“European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension”, European Journal of Heart failure, March 16, 2023 Read Post »

Can self-compassion help us better understand the impact of pulmonary hypertension on those with the condition and their carers? A cross-sectional analysis, Pulmonary Circulation, March 6, 2023

A study titled “Can self-compassion help us better understand the impact of pulmonary hypertension on those with the condition and their carers? A cross-sectional analysis” was recently published on Pulmonary Circulation. It was conducted on adults with pulmonary hypertension (n = 65) and caregivers (n = 29), who completed self-report measures on demographic and clinical factors, anxiety, depression, self-compassion,

Can self-compassion help us better understand the impact of pulmonary hypertension on those with the condition and their carers? A cross-sectional analysis, Pulmonary Circulation, March 6, 2023 Read Post »

“Health Literacy and Shared Decision-making: Exploring the Relationship to Enable Meaningful Patient Engagement in Healthcare”, Journal of General Internal Medicine

The authors of a study titled “Health Literacy and Shared Decision-making: Exploring the Relationship to Enable Meaningful Patient Engagement in Healthcare” presents an integrated model to strengthen and sustain patient engagement in health care by drawing on the strengths of both concepts. This includes addressing patients’ skills and capacities, they say, alongside modifications to written

“Health Literacy and Shared Decision-making: Exploring the Relationship to Enable Meaningful Patient Engagement in Healthcare”, Journal of General Internal Medicine Read Post »

Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH), in Respiratory Medicine, January 2023

This Phase 1 study evaluated efficacy/safety of inhaled single-dose MK-5475, an investigational, small-molecule stimulator of soluble guanylate cyclase designed for inhaled delivery via a dry-powder inhaler device, in participants with pulmonary arterial hypertension. The findings reveal that treatment with inhaled single-dose MK-5475 reduced pulmonary vascular resistance and increased pulmonary blood volume. Compared to the placebo, MK-5475 was

Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH), in Respiratory Medicine, January 2023 Read Post »

“Impact of Pulmonary Arterial Hypertension on Employment, Work Productivity, and Quality of Life – Results of a Cross-Sectional Multi-Center Study”, Frontiers in Psychiatry

Data on burden of pulmonary arterial hypertension are mostly limited to physical and clinical endpoints as well as quality of life, and research on employment, work productivity, and educational background is scarce, say the authors of this article for “Frontiers in Psychiatry”. The aim of this study was to assess the impact of pulmonary arterial

“Impact of Pulmonary Arterial Hypertension on Employment, Work Productivity, and Quality of Life – Results of a Cross-Sectional Multi-Center Study”, Frontiers in Psychiatry Read Post »

“Patient Design: The Importance of Including Patients in Designing Health Care”, Journal of Medical Internet Research

In this interesting article titled “Patient Design: The Importance of Including Patients in Designing Health Care”, the authors describe the paradigm shift that has taken place with the rise of internet from the traditional view of medicine, where doctors had little idea what the patient’s problem really was and “only doctors could know what was

“Patient Design: The Importance of Including Patients in Designing Health Care”, Journal of Medical Internet Research Read Post »

European Respiratory Society (ERS) Annual Congress 2023, September 9-13, 2023

The European Respiratory Society (ERS)’s Annual Congress is an event that brings together the world’s respiratory experts to showcase all the latest advances in respiratory medicine and science.  Pulmonary vascular diseases are listed among among the congress’ “Priority topics for 2023”, and there will be sessions dedicated to pulmonary hypertension. Learn more about the congress

European Respiratory Society (ERS) Annual Congress 2023, September 9-13, 2023 Read Post »

TRANSLATE »
Scroll to Top